Innovator biologics, biosimilars, biobetters, intended copies and non-biologic complex drugs (NBCD). Regulatory pathway aside policies from HTA bodies and payers signal they will treated as generic-like. Keep in mind that biosimilar entries may impact a therapeutic area in which you participate whether or not you market a biologic medicine. What can Canada learn from the EU experience?
Need to secure resources for your next product launch? Whether your company is a Start Up or is already established in Canada, Pangaea has developed detailed critical paths and established processes to objectively evaluate the commercial potential and required resources for a successful commercialization
Struggling to stay on top of all of the changes in the healthcare environment? The volume, pace and implications of change are causing brand teams, departments and entire organizations to be reactive. The Pangaea team proactively monitors changes in this increasingly complex healthcare environment and can help you to make well informed decisions
Pangaea has a professional and very knowledgeable group currently working with Celgene in different spheres of our business. The consulting team has provided sound advise on matters related to LOE and activities in the retail space.
Overall, Celgene holds a true partnership with Pangaea and will continue to count on their expertise to support our organization going forward.– John Ryan, Director, Finance & Operations, Celgene